Effects of L-glutamate on the responses to nerve stimulation in rat isolated atria.
In rat atria isolated with their sympathetic fibres the chronotropic responses to nerve stimulation with pulses of 2 ms duration were reduced in a concentration-dependent manner by 10 microM to 1 mM L-glutamate (Glu) and by 0.01 to 1.00 microM (R,S)-3-hydroxy-5-methoxyloxasole-4-propionic acid (AMPA), whereas they were unaffected by other agonists of Glu receptors such as 1 microM to 1 mM N-methyl-D-aspartic acid (NMDA), 10 microM to 1 mM kainate and 1 to 100 microM (+/-)-2-amino-4-phosphonobutyric acid (AP4). The reductions in the atrial responses to nerve stimulation caused by Glu were not accompanied by alterations in either the basal efflux of [3H]noradrenaline or its overflow in response to the stimulation. The sensitivity of the atria to exogenous noradrenaline was not modified by either Glu or AMPA. The decreases in the chronotropic responses caused by Glu and by AMPA were prevented by both the non-selective Glu receptor antagonist, 100 microM kynurenic acid, and the selective AMPA receptor antagonist, 10 to 50 microM 6,7-dinitroquinoxaline-2,3-dione (DNQX). In addition, the adenosine receptor antagonist, 8-phenyltheophylline (10 microM), as well as the muscarinic acetylcholine receptor antagonist, atropine (3 microM), prevented the inhibitory effects of both Glu and AMPA on the chronotropic responses of rat isolated atria. Since both adenosine and acetylcholine are known to exert negative inotropic and chronotropic effects in cardiac tissues, it is proposed that Glu could contribute, through the interaction with receptors of the AMPA type, to facilitate the release of adenosine and acetylcholine from the atria.(ABSTRACT TRUNCATED AT 250 WORDS)
Lorenzo
P S
PS
Instituto de Investigaciones Farmacológicas, CONICET, Buenos Aires, Argentina.
Butta
N V
NV
Adler-Graschinsky
E
E
D000320:Adrenergic Fibers / Q000502:physiology*; D000613:Aminobutyrates / Q000494:pharmacology; D000818:Animals; D016275:Atrial Function; D004558:Electric Stimulation; D005260:Female; D005971:Glutamates / Q000494:pharmacology*; D018698:Glutamic Acid; D006325:Heart Atria / Q000187:drug effects* / Q000294:innervation; D006339:Heart Rate / Q000187:drug effects*; D066298:In Vitro Techniques; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D018727:Muscarinic Antagonists; D016202:N-Methylaspartate / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D058915:Purinergic P1 Receptor Antagonists; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
D000613:Aminobutyrates; D005971:Glutamates; D018727:Muscarinic Antagonists; D058915:Purinergic P1 Receptor Antagonists; D011810:Quinoxalines; D018698:Glutamic Acid; C056723:FG 9041; D016202:N-Methylaspartate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; C012729:2-amino-4-phosphonobutyric acid; D007608:Kainic Acid; D009638:Norepinephrine